Aurobindo Pharma Limited — Important, 10-11-2024: Updates

Aurobindo Pharma announced a corrigendum to their unaudited consolidated financial results for the half-year ended September 30, 2024, correcting a typographical error in profit figures. This correction does not impact the overall financial results. Revenue increased to approximately ₹153,630.9 million, with a profit of ₹17,351.7 million for the period. The company also acquired stakes in multiple subsidiaries and completed a buyback of shares totaling ₹9,302.4 million.